A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.

A third drug, pretomanid, received emergency authorization from the FDA for specific use within a regimen against highly drug ...

My parents are both retired medical professionals who are in their early 70s. My father has diabetes that he manages with ...

Experts fear a resurgence of infections in low-income countries if the ban were to continue. The waiver remains in place, ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

This is just a sampling of medical advancements in 2024 chosen for their common presence in the American population. It is ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...